Cisplatin Pfizer

Cisplatin

Monotherapy or in combination w/ other chemotherapeutic agents for metastatic non-seminomatous germ cell carcinoma, advanced stage refractory ovarian & bladder carcinoma, refractory squamous cell head & neck carcinoma.

Adult & childn Monotherapy 50-100 mg/m² as single IV infusion every 3-4 wk over 6-8 hr or 15-20 mg/m² slow IV infusion daily for 5 days every 3-4 wk. Testicular cancer In combination w/ vinblastine, bleomycin, actinomycin D. Ovarian cancer In combination w/ cyclophosphamide, doxorubicin, hexamethylmelamine, 5-fluorouracil. Head & neck cancer In combination w/ bleomycin, MTX.

Hypersensitivity to cisplatin- or platinum-containing compd. Hearing disorders, bone marrow depression, generalised infections. Renal impairment. Pregnancy & lactation.

Anaphylaxis-like reactions, prior or family history of atopy. Discontinue use if severe nausea & vomiting occur. Cessation of treatment if peripheral neuropathy, postural hypotension, myasthenic syndromes, seizures & vision loss occur. Cumulative ototoxicity; myelosuppression, severe thrombocytopenia & leucopenia; Coombs' +ve haemolytic anaemia, haemolysis; hypomagnesemia & hypocalcaemia; CV toxicity. Patients recently exposed to infections eg, chicken pox & herpes zoster. Invasive procedures. Avoid dental procedures during therapy. Ensure hydration prior to, during & after therapy. Monitor renal function (including GFR), BUN, serum creatinine & CrCl; electrolytes (Mg, Na, K, Ca), auditory function, RBC, WBC & platelets, liver function & neurological status prior to initial therapy then before subsequent doses. Periodically monitor baseline audiogram for auditory deterioration. Not to be used w/ live or live-attenuated vaccines. Avoid use w/ alcohol & aspirin. Concomitant use w/ other potentially nephrotoxic drugs. Preexisting hepatic & renal dysfunction. May affect male fertility. Women of childbearing potential should use effective contraception. Avoid use during pregnancy. Not to be used during lactation. Possible delayed-onset hearing loss in paed.

Stomatitis, vomiting, nausea, anorexia, hiccups, diarrhoea; acute renal toxicity; thrombotic microangiopathy (haemolytic uraemic syndrome), bone marrow failure, neutropenia, Coombs' +ve haemolytic anaemia, myelosuppression, mild bone marrow toxicity; infection, sepsis; anaphylactic & anaphylactic-like reactions; unilateral or bilateral tinnitus &/or hearing loss; convulsion, leukoencephalopathy, reversible posterior leukoencephalopathy syndrome, haemorrhagic & ischaemic stroke, ageusia, cerebral arteritis, myelopathy; retinal toxicity; CV abnormalities; Raynaud's phenomenon, VTE; pulmonary embolism; mild & transient serum AST & ALT elevations; mild alopecia; myalgia, muscle spasm; spermatogenesis & azoospermia impairment; dehydration, serious electrolyte disturbances; pyrexia, asthenia, malaise, local effects.

Exacerbated nephrotoxic & ototoxic effects w/ aminoglycosides or loop diuretics. Greater renal toxicity & increased hearing loss w/ ifosfamide. Enhanced toxicity of bleomycin & MTX. Reduced lithium blood levels w/ bleomycin & etoposide. Decreased serum conc of phenytoin. Raised blood uric acid conc w/ antigout agents eg, allopurinol, colchicine, probenecid, sulfinpyrazone. Monitor/check INR w/ oral anticoagulants eg, coumarins/warfarin. Reduced clearance of paclitaxel.

Cytotoxic Chemotherapy

L01XA01 - cisplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.

B